The dual c-Met/vascular endothelial growth factor receptor 2 (VEGFR-2) TK inhibition is a good strategy to overcome therapeutic resistance to small molecules VEGFR-2 inhibitors. In this study, we designed 3-substituted quinazoline-2,4(1
H
,3
H
)-dione derivatives as dual c-Met/VEGFR-2 TK inhibitors. We introduced new synthetic methods for reported derivatives of 3-substituted quinazoline-2,4(1
H
,3
H
)-dione
2a
–
g
, in addition to the preparation of some new derivatives namely,
3
and
4a
–
j
. Three compounds namely,
2c
,
4b
, and
4e
showed substantial amount of inhibition for both c-Met and VEGFR-2 TK (IC
50
range 0.052–0.084 µM). Both compounds
4b
,
4e
showed HB with highly conserved residue Asp1222 in the HB region of c-Met TK. For VEGFR-2 TK, compound
4b
showed HB with a highly conserved residue Asp1046 in the HB region. Compound
4e
showed HB with Glu885 and Asp1046. Moreover,
in silico
prediction of pharmacokinetic and physicochemical parameters of target compounds was carried out using SwissADME website. The quinazoline-2,4(1
H
,3
H
)-dione derivatives are promising antiproliferative candidates that require further optimisation.
Highlights
New 3-substituted quinazoline-2,4(1
H
,3
H
)-dione derivatives were synthesised and characterised.
Compounds
4b
and
4e
showed higher cytotoxic activity than cabozantinib against HCT-116 colorectal cell lines.
Both compounds
4b
and
4e
showed less toxicity to WI38 normal cell line compared to HCT 116 colon cancer cell line.
Compound
4b
was superior to cabozantinib in VEGFR-2 inhibition while compound
2c
was equipotent to cabozantinib.
Compounds
4b
and
4e
showed remarkable c-Met inhibitory activity.
Compounds
4b
and
4e
arrested cell cycle and induced significant levels of apoptosis.
In silico
ADME prediction revealed high oral bioavailability and enhanced water solubility of target compounds as compared to cabozantinib.
Target compounds interacted with both c-Met and VEGFR-2 active site in similar way to ca...